Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (SRPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments – Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both
How this was made
The 30-second read
Why it matters
The guidance raise and expense reduction provide a clearer growth trajectory, likely prompting investors to reassess valuation multiples.
Market read
Guidance updates are a primary catalyst for price movement in biotech stocks, making this filing highly relevant for short‑term traders.
What to watch
Potential regulatory delays for DM1 and FSHD programs could temper upside.
Sarepta reported approximately $323.8 million of third-quarter net product revenue, a GAAP operating loss of ($9.0) million and non-GAAP operating income of $22.9 million, while raising the low end of full-year product-revenue guidance and lowering the high end of expense guidance.
PMO performance supported a higher full-year net product revenue floor and non-GAAP operating income improved, but total revenue and net product revenue declined from the prior-year quarter amid lower ELEVIDYS sales following the updated ambulatory-only label.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $381.4M | – | $(18.0) million (5)% |
| Net product revenues, three months ended September 30, 2026GAAP | approximately $323.8 million | – | – |
| Collaboration and other revenues, three months ended September 30, 2026GAAP | $57.6M | – | – |
| Cost of sales (excluding amortization of in-license rights), three months ended September 30, 2026GAAP | $188.5M | – | $37.7 million |
| Research and development expenses, three months ended September 30, 2026GAAP | $82.5M | – | $(136.4) million |
| Research and development expenses, three months ended September 30, 2026non-GAAP | $71.6M | – | $(134.9) million |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $118.6M | – | $26.7 million |
| Selling, general and administrative expenses, three months ended September 30, 2026non-GAAP | $97.6M | – | $20.5 million |
| Operating loss, three months ended September 30, 2026GAAP | ($9.0) million | – | $94.4 million (91)% |
| Operating income, three months ended September 30, 2026non-GAAP | $22.9M | – | $58.6 million |
| Net loss, three months ended September 30, 2026GAAP | ($28.5) million | – | $22.1 million (44)% |
| Net income, three months ended September 30, 2026non-GAAP | $15.6M | – | $28.5 million |
| Diluted loss per share, three months ended September 30, 2026GAAP | $(0.27) | – | $0.23 (46)% |
| Non-GAAP diluted earnings per share, three months ended September 30, 2026non-GAAP | $0.13 | – | $0.26 |
| GAAP effective tax rate, three months ended September 30, 2026GAAP | (10.5)% | – | – |
| Non-GAAP effective tax rate, three months ended September 30, 2026non-GAAP | 31.4% | – | – |
| Total revenues, nine months ended September 30, 2026GAAP | $1.51B | – | $(241.9) million (14)% |
| Net product revenues, nine months ended September 30, 2026GAAP | $983M | – | – |
| Collaboration and other revenues, nine months ended September 30, 2026GAAP | $530.4M | – | – |
| Cost of sales (excluding amortization of in-license rights), nine months ended September 30, 2026GAAP | $446.7M | – | $5.8 million |
| Research and development expenses, nine months ended September 30, 2026GAAP | $327.8M | – | approximately $(868.9) million |
| Research and development expenses, nine months ended September 30, 2026non-GAAP | $285.8M | – | $(851.6) million |
| Selling, general and administrative expenses, nine months ended September 30, 2026GAAP | $335.2M | – | $(28.2) million |
| Selling, general and administrative expenses, nine months ended September 30, 2026non-GAAP | $271.7M | – | $(25.9) million |
| Litigation settlement charge, nine months ended September 30, 2026GAAP | $39M | – | – |
| Operating income, nine months ended September 30, 2026GAAP | $362.7M | – | $650.9 million |
| Operating income, nine months ended September 30, 2026non-GAAP | $507.1M | – | $629.6 million |
| Net income, nine months ended September 30, 2026GAAP | $297.6M | – | $598.8 million |
| Net income, nine months ended September 30, 2026non-GAAP | $479.6M | – | $609.8 million |
| Diluted earnings per share, nine months ended September 30, 2026GAAP | $2.78 | – | $5.84 |
| Non-GAAP diluted earnings per share, nine months ended September 30, 2026non-GAAP | $3.91 | – | $5.23 |
| Cash, cash equivalents, restricted cash and investments, as of September 30, 2026GAAP | $998.7M | – | – |
| Current portion of long-term debt, as of September 30, 2026GAAP | $158M | – | – |
| Long-term debt, as of September 30, 2026GAAP | $699.4M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| PMO net product revenuesThe Company cited strong PMO performance as the driver of raising the low end of full-year total net product revenue guidance by $50.0 million. | approximately $240.3 million | – | – |
| ELEVIDYS net product revenueLower ELEVIDYS sales volume reflected the continued impact of the updated label, which only includes the ambulatory patient population for treatment. | $83.5M | – | – |
Full-year 2026 outlook
- Revenue$1.25 billion to $1.3 billion
- Operating expenses$800 million to $825 million combined non-GAAP R&D and SG&A expenses
- NoteELEVIDYS net product revenue in the fourth quarter to trend in line with the third quarter, consistent with previous guidance and subject to normal variability associated with one-time gene therapy.
- NoteMultiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected in the fourth quarter of 2026.
What drove it
- Third-quarter total revenue declined primarily because ELEVIDYS sales volume was lower following the updated label limited to ambulatory patients.
- The total-revenue decrease was partially offset by a $31.4 million increase in contract manufacturing revenues associated with increased commercial ELEVIDYS supply delivered to Roche.
- Third-quarter R&D expense declined principally because the prior-year period included a $100.0 million Arrowhead milestone payment, with additional reductions in manufacturing and clinical expenses following pipeline reprioritization.
- Nine-month collaboration revenue included $365.0 million recognized related to Roche's declined option for certain program rights and the milestone for the first commercial dosing of ELEVIDYS in Japan.
- The Company raised the low end of net product revenue guidance by $50.0 million, citing strong PMO performance, and reduced the high end of combined non-GAAP R&D and SG&A expense guidance by $25.0 million.
Concerns
- ELEVIDYS sales volume declined because the updated label only includes the ambulatory patient population for treatment.
- Third-quarter cost of sales increased by $37.7 million and included a $62.0 million take-or-pay charge related to non-cancelable Catalent manufacturing obligations for inventories the Company elected not to manufacture.
- Cost of sales also reflected increased ELEVIDYS shipments to Roche and write-offs of certain batches that did not meet quality specifications under the Roche collaboration agreement.
- The Company recorded a $39.0 million litigation settlement charge during the nine-month period.
- ELEVIDYS prescribing information includes a boxed warning for acute serious liver injury and acute liver failure.
What to watch
- Fourth-quarter 2026 multiple ascending dose data from SRP-1003 in DM1, including DMPK knockdown and splicing correction.
- Fourth-quarter 2026 multiple ascending dose data from SRP-1001 in FSHD, including DUX4 knockdown.
- Whether fourth-quarter ELEVIDYS net product revenue trends in line with the third quarter.
- Progress in preparations for potential Phase 3 development of SRP-1003 and SRP-1001, including clinical-supply manufacturing.
- Execution against the $1.25 billion to $1.3 billion full-year total net product revenue range and $800 million to $825 million combined non-GAAP R&D and SG&A expense range.
Balance sheet and cash flow
- The Company reported positive cash flow for the third quarter of 2026; no cash-flow amount was reported.
- Cash, cash equivalents, restricted cash and investments were $998.7 million as of September 30, 2026, compared with $953.8 million as of December 31, 2025.
- Cash and cash equivalents were $472.8 million and short-term investments were $406.0 million as of September 30, 2026.
- Current portion of long-term debt was $158.0 million and long-term debt was $699.4 million as of September 30, 2026.
Analysis
Third-quarter total revenue was $381.4 million, down from $399.4 million in the prior-year period. Net product revenues were approximately $323.8 million, comprising approximately $240.3 million from PMO products and $83.5 million from ELEVIDYS. The Company attributed the revenue decline primarily to lower ELEVIDYS volume after the updated label limited treatment to ambulatory patients. A $31.4 million increase in contract manufacturing revenue associated with commercial ELEVIDYS supply delivered to Roche partially offset that decline.
Profitability improved sharply from the prior-year quarter despite the top-line decline. GAAP operating loss narrowed to ($9.0) million from ($103.4) million, while non-GAAP operating income was $22.9 million versus a non-GAAP operating loss of ($35.7) million. GAAP net loss was ($28.5) million and non-GAAP net income was $15.6 million. The primary expense improvement came from R&D, which fell to $82.5 million from $218.9 million, principally because the prior-year quarter included a $100.0 million Arrowhead milestone payment and because of lower manufacturing and clinical expenses following the pipeline reprioritization.
Cost discipline was not uniform across the income statement. Third-quarter GAAP SG&A rose to $118.6 million from $91.9 million, and non-GAAP SG&A increased to $97.6 million from $77.1 million. Cost of sales increased to $188.5 million from $150.8 million, driven primarily by a $62.0 million take-or-pay charge related to Catalent obligations, as well as increased Roche shipments and certain product-batch write-offs. These items remain important to monitor alongside the expected level of ELEVIDYS revenue.
For the nine months, total revenue was $1,513.4 million, down from $1,755.3 million, while GAAP operating income was $362.7 million and non-GAAP operating income was $507.1 million. Nine-month results included $365.0 million of collaboration revenue related to Roche's declined option and a Japan commercial-dosing milestone, while the period also included a $39.0 million litigation settlement charge. The Company ended the quarter with $998.7 million in cash, cash equivalents, restricted cash and investments and stated that it delivered positive cash flow.
Management raised the low end of full-year total net product revenue guidance by $50.0 million to $1.25 billion to $1.3 billion, citing strong PMO performance. It also lowered the high end of combined non-GAAP R&D and SG&A guidance by $25.0 million to $800 million to $825 million. ELEVIDYS fourth-quarter net product revenue is expected to trend in line with the third quarter. Near-term execution centers on fourth-quarter multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD, as Sarepta prepares both programs for potential Phase 3 development.
Management, verbatim
After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.
Michael Severino, M.D., chief executive officer, Sarepta
This quarter, we saw continued strength in our commercial execution.
Michael Severino, M.D., chief executive officer, Sarepta
We have work to do, and I want us to be measured by execution, but I believe Sarepta has the commercial foundation, pipeline opportunities and financial strength to deliver meaningful long-term value.
Michael Severino, M.D., chief executive officer, Sarepta
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported financial metrics were not provided.
- Gross profit and gross margin were not reported.
- Operating cash flow amount was not reported.
- Free cash flow amount was not reported.
- Capital return activity, including share repurchases and dividends, was not reported.
- Prior outlook was not provided, so no comparison of actual results with prior guidance is available.
- Year-over-year changes for PMO net product revenues and ELEVIDYS net product revenue were not reported on their respective line items.
- Debt maturity schedule and interest rates were not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Sarepta Therapeutics (NASDAQ:SRPT) disclosed its Q3 2026 financials via an SEC Form 8‑K, including revenue, operating results, cash position, and updated full‑year guidance.
Ticker impact
Sarepta Therapeutics reported Q3 2026 results and raised the low end of its full-year net product revenue guidance by $50 million.
likely upside as investors price in higher revenue guidance and lower expense guidance.
The raised revenue guidance and lowered expense guidance indicate stronger cash flow, which typically supports a higher stock valuation.
Market effects
Positive for the rare‑disease biotech sector as Sarepta's guidance lift may boost peer sentiment.
US biotech market may see modest gains from the guidance update.
Limited to investors tracking rare‑disease therapeutics.
Counterpoint
If the raised guidance is already priced in, the stock could face a short‑term pullback.
Key entities
- CompanySarepta Therapeutics
Biotech firm focused on rare‑disease gene therapies.
